BOLT Projected Dividend Yield

Bolt Biotherapeutics Inc ( NASDAQ : BOLT )

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Co.'s pipeline candidates are built on its expertise in myeloid biology and cancer drug development. Its pipeline includes trastuzumab imbotolimod (formerly BDC-1001), a human epidermal growth factor receptor 2 - targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. Trastuzumab imbotolimod is in Phase 2 clinical. BDC-3042, an agonist antibody targeting Dectin-2, is in a Phase 1 dose-escalation trial.

21 YEAR PERFORMANCE RESULTS

BOLT Dividend History Detail
BOLT Dividend News
BOLT Competitors News
# of Shares: 0 Closing Price: 0.59 Current Market Value: 0.00 Cost Basis: 0.00 Date Acquired:
Dividend Cash Flow
Year Annual Dividend Dividend Growth # of Shares Annual Dividend Income Yield On Cost %
2014 0.00 0% 0 $ 0.00 0.00%
2015 0.00 0% 0 $ 0.00 0.00%
2016 0.00 0% 0 $ 0.00 0.00%
2017 0.00 0% 0 $ 0.00 0.00%
2018 0.00 0% 0 $ 0.00 0.00%
2019 0.00 0% 0 $ 0.00 0.00%
2020 0.00 0% 0 $ 0.00 0.00%
2021 0.00 0% 0 $ 0.00 0.00%
2022 0.00 0% 0 $ 0.00 0.00%
2023 0.00 0% 0 $ 0.00 0.00%
2024 0.00 0% 0 $ 0.00 0.00%
2025 0.00 0% 0 $ 0.00 0.00%
2026 0.00 0% 0 $ 0.00 0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection)
0.00
Year
Declaration Date
Ex-Dividend Date
Record Date
Payable Date
Dividend $ Amount
Total:
0.0000
X
Search Dividend Investor